- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
858 Therapeutics Inc.
Headquarters: San Diego, CA, United States
Website: https://8five8tx.com/
Year Founded: 2019
Status: Private
BioCentury | Feb 26, 2025
Management Tracks
Lindsay Androski named CEO of Arbutus
Plus: CMO Maria Koehler steps down at Repare, and updates from Isomab, Crescent, Ottimo and Senti Bio
BioCentury | Sep 26, 2024
Finance
Eyes on Europe: Asabys’ €180M fund, Genespire’s record series B
BioCentury’s weekly Venture Report also includes Arch’s latest fund, Flagship-backed Mirai, series Bs for Vicebio and 858, and more
BioCentury | Dec 21, 2023
Management Tracks
Larson leaving LianBio as CFO
Plus: Claypoole becomes CEO of Bioventus, and updates from Boston Pharma, Atlas, Quest, Scribe, 858 and more
BioCentury | Mar 1, 2023
Emerging Company Profile
Tachyon’s VC round, CIRM grant drive first-in-class oncology program to clinic
Team including Quanticel co-founders has begun Phase I testing of KDM4 program that had traveled through Celgene, BMS
BioCentury | Apr 6, 2022
Management Tracks
Sabatini out at MIT
Plus Avidity expands role of MacLean and updates from Exscientia, eFFECTOR, Sofinnova and more
BioCentury | Oct 19, 2021
Product Development
Quick Takes: And then there were two — bluebird readies for split
Vertex’s Phase I diabetes data shine, plus United Therapeutics, Ipsen, Omeros and more
BioCentury | Sep 21, 2021
Emerging Company Profile
858: Versant’s second start-up targeting RNA-modifying proteins
Emerging Company Profile: Building on a predecessor epitranscriptomics company, 858 brings together VCs and familiar team
Items per page:
1 - 10 of 10